Molecular
TREC DNA analysis
TREC DNA is a marker ofnewly generated T cellsand provides an indicationof thymic output.
Clinical study
Rigorous clinical researchin healthy adults
A twelve-month clinical programme involving 260 healthy adults evaluated T-Booster through two randomised, double-blind studies, including a placebo-controlled comparison and an investigation of dose-dependent effects.
RandomisedParticipants assigned to T-Booster or placebo.
Double-blindDesigned to reduce expectation and assessment bias.
Placebo controlA comparison group supports interpretation.
Multi-readoutTREC DNA, CBC and questionnaire outcomes.
Programme at a glance
Biological andquestionnaire outcomes
The programme was conducted at BSMMU in Dhaka using randomisation, double blinding and a placebo comparator to strengthen the interpretation of change over time.
Biological assessment combined TREC DNA with CBC and immune-cell measures, while an 18-question participant survey captured changes in everyday wellbeing. Participant involvement is complete; final laboratory analysis and scientific interpretation are being prepared.
Why the comparator matters
Repeating the same assessments in blinded T-Booster and placebo groups helps separate programme-related change from normal variation and participant expectation.
Programme at a glance
One programme withtwo randomised studies
The clinical work was carried out at BSMMU in Dhaka across a twelve-month period. A randomised, double-blind, placebo-controlled comparison sat at its centre, supported by a second randomised study examining dose-dependent effects.
Every volunteer gave a 6 mL blood sample at baseline and again at the end of the intervention. Those paired samples supported TREC DNA and complete blood count analysis, while a lifestyle questionnaire recorded how participants felt across eighteen categories.
Participant involvement is now complete. Final laboratory analysis and scientific interpretation remain in progress.
Study journey
Participant screeningto scientific analysis
A clear before-and-after pathway with repeat measurements and a placebo comparator.
Volunteers were screened and gave written informed consent before blinded allocation to T-Booster or placebo. Baseline blood and questionnaire data were collected, the intervention ran daily for four months, and the same assessments were then repeated.
Assessment teams stayed blinded throughout, so the comparison between the two groups can be interpreted without knowledge of allocation.
Repeat measuresThe same biological and questionnaire assessments were collected before and after the intervention.
Blinding maintainedAssessment teams remained unaware of allocation while the participant groups were compared.
Primary and supporting outcomes
Three complementarylayers of evidence
No single endpoint tells the whole story. The study combines a molecular marker, blood measures and participant experience.
Blood
CBC and lymphocytes
CBC and lymphocyte measuresprovide wider laboratorycontext for immune-celland blood findings.
Human experience
Questionnaire outcomes
Questionnaires recordedchanges in energy and sleep,stress, pain, mood and skinand other wellbeing areas.
Age-group analysis
Age-group findings fromthe T-Booster study
Preliminary analysis indicates measurable changes across the studied age groups, with the strongest relative increase observed among participants aged 48–57. Baseline, placebo and T-Booster values are shown side by side for every age group. Final laboratory analysis and statistical interpretation are still being completed, so these figures should not be read as confirmed clinical outcomes.
TREC DNA by age group
All current values and percentage comparisons are retained in one structured table.
5Age groups
4 moComparison
34.28%Largest current increase
| Age group | Baseline | Placebo 4 mo | Placebo change | T-Booster 4 mo | T-Booster change | T-Booster vs placebo |
|---|---|---|---|---|---|---|
| 18–27 | 39.80 | 39.55 | −0.63% | 43.51 | +9.32% | +10.01% |
| 28–37 | 25.78 | 25.44 | −1.32% | 29.53 | +14.55% | +16.08% |
| 38–47 | 17.29 | 16.98 | −1.79% | 21.77 | +25.91% | +28.21% |
| 48–57 | 11.67 | 11.44 | −1.97% | 15.67 | +34.28% | +36.98% |
| 58+ | 6.72 | 6.59 | −1.93% | 8.05 | +19.79% | +22.15% |
Swipe horizontally to view the complete table.
The largest percentage increase in the current age-group analysis is 34.28% in ages 48–57. Placebo values changed only marginally over the same period. Findings remain preliminary until final statistical interpretation and peer review.
Preliminary signals
Preliminary findingsacross study readouts
The current website reports improvement in the age-group TREC analysis, CBC parameters and questionnaire-reported wellbeing. These results remain preliminary and have not yet been published or peer reviewed.
34.28%
Largest age-band increase
TREC DNA analysis
The largest percentage gainin the current age analysiswas seen at ages 48–57.
CBC
Blood analysis
CBC findings
Final statistical tablesand complete interpretationare still being finalised.
8
Reported categories
Questionnaire gains
Questionnaire results showedimprovement across severalwellbeing categories.
Volunteer feedback
Questionnaire outcomesafter T-Booster
Percentages represent participants who reported each concern at baseline and improvement at the end of the programme. These values come from the final questionnaire analysis.
Participant experience is recorded alongside TREC DNA and CBC blood measures so that laboratory outcomes and lived experience can be interpreted together once final analysis is complete.
Volunteer stories & media coverage
Two films from theclinical-study journey
The official clinical-study page features national media coverage and volunteer interviews. Personal experiences are not a substitute for controlled analysis.
Media coverage
Public discussion of thymus health, T-Booster and the clinical programme.
Volunteer interviews
Participant perspectives presented as personal accounts, not clinical proof.